The Score: Rivian, Amazon, Trump Media and More Stocks That Defined the Week
Novo Nordisk —the Danish pharmaceutical giant behind Wegovy and other buzzy weight-loss treatments—will now be able to sell the medication in the world’s second-largest economy. Novo Nordisk’s Ozempic drug—which contains the same semaglutide active ingredient as Wegovy—was approved to treat diabetes in China in 2021. The surging appetite for Wegovy in other markets has forced Novo Nordisk to restrict supply to protect current patients’ access to the drug while the company scrambles to increase production.
The Wall Street Journal•